Biodistribution and Efficacy of Low Temperature-Sensitive Liposome Encapsulated Docetaxel Combined with Mild Hyperthermia in a Mouse Model of Prostate Cancer

Ranjan, Ashish; Benjamin, Compton J.; Negussie, Ayele H.; Chokshi, Saurin; Chung, Paul H.; Volkin, Dmitry; Yeram, Nitin; Linehan, W. Marston; Dreher, Matthew R.; Pinto, Peter A.; Wood, Bradford J.

doi:10.1007/s11095-016-1971-8

Cited by 9 publications

(4 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, although the first or second generation of liposomes displayed improved pharmacokinetics (ie, decreased clearance and higher tumor accumulation), [12][13][14] further development of nanoparticles is still an ongoing story with taxanes. Thus, more sophisticated forms have been developed such as co-loaded liposomes (eg, docetaxel + palmitoyl ascorbate, 15 paclitaxel + rapamycin, 16 docetaxel + BCL-2 SiRNA 17 ), triggered liposomes (eg, pH sensitive 18 or thermosensitive 19 ) and targeted liposomes. Many moieties (eg, small-molecule ligands, peptides 20 and monoclonal antibodies) have been used over the last years to actively target cancer cells through different strategies, including targeting several receptors like folate receptors, 21,22 integrin 23 and transferrin.…”

Section: Introductionmentioning

confidence: 99%

Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer

Rodallec¹,

Brunel²,

Giacometti³

et al. 2018

IJN

View full text Add to dashboard Cite

BackgroundTrastuzumab plus docetaxel is a mainstay to treat HER2-positive breast cancers. However, developing nanoparticles could help to improve the efficacy/toxicity balance of this doublet by improving drug trafficking and delivery to tumors. This project aimed to develop an immunoliposome in breast cancer, combining docetaxel encapsulated in a stealth liposome engrafted with trastuzumab, and comparing its performances on human breast cancer cell lines with standard combination of docetaxel plus trastuzumab.MethodsSeveral strategies to engraft trastuzumab to pegylated liposomes were tested. Immunoliposomes made of natural (antibody nanoconjugate-1 [ANC-1]) and synthetic lipids (ANC-2) were synthesized using standard thin film method and compared in size, morphology, docetaxel encapsulation, trastuzumab engraftment rates and stability. Antiproliferative activity was tested on human breast cancer models ranging from almost negative (MDA-MB-231), positive (MDA-MB-453) to overexpressing (SKBR3) HER2. Finally, cell uptake of ANC-1 was studied by electronic microscopy.ResultsANC-1 showed a greater docetaxel encapsulation rate (73%±6% vs 53%±4%) and longer stability (up to 1 week) as compared with ANC-2. Both ANC presented particle size ≤150 nm and showed similar or higher in vitro antiproliferative activities than standard treatment, ANC-1 performing better than ANC-2. The IC50s for docetaxel combined to free trastuzumab were 8.7±4, 2±0.7 and 6±2 nM with MDA-MB-231, MDA-MB-453 and SKBR3, respectively. The IC50s for ANC-1 were 2.5±1, 1.8±0.6 and 3.4±0.8 nM and for ANC-2 were 1.8±0.3 nM, 2.8±0.8 nM and 6.8±1.8 nM with MDA-MB-231, MDA-MB-453 and SKBR3, respectively. Cellular uptake appeared to depend on HER2 expression, the higher the expression, the higher the uptake.ConclusionIn vitro results suggest that higher antiproliferative efficacy and efficient drug delivery can be achieved in breast cancer models using nanoparticles.

show abstract

Section: Introductionmentioning

confidence: 99%

Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer

Rodallec¹,

Brunel²,

Giacometti³

et al. 2018

IJN

View full text Add to dashboard Cite

show abstract

“…123 Mild hyperthermia of solid tumors could also increase drug delivery efficiency. 128,129 Homogenous near-infrared light exposure of solid tumors has been shown to enhance homogeneous delivery of an antibody−photoabsorber conjugate in solid tumors, resulting in improved therapeutic efficacy in treating head and neck cancer with photoimmunotherapy. 130 The tumor microenvironment plays a key role in the proliferation, invasion, and metastasis of aggressive tumors.…”

Section: ■ Future Perspectives Of Drug Delivery In Cancer Therapymentioning

confidence: 99%

“…It has been shown that pharmacologically induced hypertension could improve drug delivery into solid tumors . Mild hyperthermia of solid tumors could also increase drug delivery efficiency. , Homogenous near-infrared light exposure of solid tumors has been shown to enhance homogeneous delivery of an antibody–photoabsorber conjugate in solid tumors, resulting in improved therapeutic efficacy in treating head and neck cancer with photoimmunotherapy …”

Section: Future Perspectives Of Drug Delivery In Cancer Therapymentioning

confidence: 99%

Drug Delivery in Cancer Therapy, Quo Vadis?

Lü

Qiao

2018

Mol. Pharmaceutics

View full text Add to dashboard Cite

The treatment of malignancies has undergone dramatic changes in the past few decades. Advances in drug delivery techniques and nanotechnology have allowed for new formulations of old drugs, so as to improve the pharmacokinetics, to enhance accumulation in solid tumors, and to reduce the significant toxic effects of these important therapeutic agents. Here, we review the published clinical data in cancer therapy of several major drug delivery systems, including targeted radionuclide therapy, antibody-drug conjugates, liposomes, polymer-drug conjugates, polymer implants, micelles, and nanoparticles. The clinical outcomes of these delivery systems from various phases of clinical trials are summarized. The success and limitations of the drug delivery strategies are discussed based on the clinical observations. In addition, the challenges in applying drug delivery for efficacious cancer therapy, including physical barriers, tumor heterogeneity, drug resistance, and metastasis, are discussed along with future perspectives of drug delivery in cancer therapy. In doing so, we intend to underscore that efficient delivery of cancer therapeutics to solid malignancies remains a major challenge in cancer therapy, and requires a multidisciplinary approach that integrates knowledge from the diverse fields of chemistry, biology, engineering, and medicine. The overall objective of this review is to improve our understanding of the clinical fate of commonly investigated drug delivery strategies, and to identify the limitations that must be addressed in future drug delivery strategies, toward the pursuit of curative therapies for cancer.

show abstract

“…Hyperthermia is a therapeutic technique in which a body is subjected to mild increases in temperature (41-45 C) for an extended length of time (15-90 min) [1][2][3][4][5]. An increase in temperature affects many biological phenomena, including blood flow oxygenation and the permeability of nanoparticles [1,6].…”

Section: Introductionmentioning

confidence: 99%

Development of custom RF coils for use in a small animal platform for magnetic resonance-guided focused ultrasound hyperthermia compatible with a clinical MRI scanner

Abraham

Loree-Spacek

Drainville

et al. 2018

International Journal of Hyperthermia

View full text Add to dashboard Cite

show abstract

Biodistribution and Efficacy of Low Temperature-Sensitive Liposome Encapsulated Docetaxel Combined with Mild Hyperthermia in a Mouse Model of Prostate Cancer

Abstract: This technique of hyperthermia sensitization and enhanced docetaxel delivery has potential for clinical translation for prostate cancer treatment.

Cited by 9 publications

References 41 publications

Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer

Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer

Drug Delivery in Cancer Therapy, Quo Vadis?

Development of custom RF coils for use in a small animal platform for magnetic resonance-guided focused ultrasound hyperthermia compatible with a clinical MRI scanner

Contact Info

Product

Resources

About